Type I Crystal of Heterocyclidene Acetamide Derivative
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a highly pure and stable form of the type I crystal of (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide with excellent TRPV1 antagonism, particularly in terms of storage stability, photostability, and thermodynamic stability, to ensure effective use as a pharmaceutical agent without polymorphic transitions and bioactivity loss.
Innovation Solution
The type I crystal is produced through a method involving dissolution in alcohol solvents or mixed solvents with acetone, followed by gradual addition of water and cooling to room temperature, resulting in a thermodynamically stable, non-hygroscopic crystal with characteristic x-ray diffraction peaks and high chemical purity, preventing polymorphic transitions and maintaining bioactivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional crystallization methods are used to obtain compound (1), then the compound can be obtained as a solid, but the crystal form obtained lacks sufficient stability (polymorphic transitions occur) and photostability
Solution Approach 1:
The patent applies parameter changes by modifying crystallization conditions (temperature, solvent composition, cooling rate) to obtain a specific crystal polymorph (type I crystal) that exhibits enhanced stability and photostability. The invention identifies specific crystallization parameters that lead to the formation of the most stable crystal form, preventing polymorphic transitions and maintaining compound integrity under various storage conditions.
Solution Approach 2:
The patent uses X-ray diffraction analysis to create a detailed structural copy or model of the crystal lattice, allowing characterization and verification of the crystal form. This copying approach enables confirmation of crystal structure, identification of polymorphic forms, and validation of crystal stability without requiring physical manipulation of the crystals themselves.
2Manufacturing precision
If the crystal is to maintain high purity and stability, then polymorphic transitions must be prevented, but this requires precise control of crystallization conditions
Solution Approach 1:
The patent applies preliminary action by establishing optimal crystallization conditions before actual crystal formation occurs. This includes pre-determining the best solvent systems, temperature profiles, and mixing rates to ensure that when crystallization occurs, the desired stable polymorph forms directly without requiring subsequent purification or transformation steps.
Solution Approach 2:
The patent employs feedback mechanisms through X-ray diffraction analysis and other characterization techniques to monitor crystal formation in real-time or post-hoc. This feedback allows verification that the intended crystal form has been obtained and enables adjustment of crystallization parameters if necessary to maintain high purity and prevent polymorphic transitions.
3Duration of action of stationary object
If the crystal form is to be maintained stable during storage and formulation, then thermodynamic stability must be ensured, but this requires identification of the most stable polymorph
Solution Approach 1:
The patent replaces mechanical or trial-and-error approaches to polymorph identification with sophisticated analytical techniques such as X-ray diffraction, differential scanning calorimetry, and spectroscopic methods. These substitution approaches provide precise, objective measurement of crystal structure and stability characteristics, enabling reliable identification and selection of the thermodynamically most stable polymorph for long-term storage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method yields a stable pharmaceutical composition with excellent TRPV1 antagonistic activity, maintaining bioavailability and formulation properties over time, suitable for treating various pain-related conditions and other TRPV1-associated disorders.
Implementation Method 1
dissolution in alcohol solvents or mixed solvents with acetone
Implementation Method 2
gradual addition of water and cooling to room temperature, resulting in a thermodynamically stable, non-hygroscopic crystal
Implementation Method 3
gradual addition of water and cooling to room temperature
Implementation Method 4
characteristic x-ray diffraction peaks
Implementation Method 5
characteristic peaks at diffraction angles (2θ) of about 7.9, about 8.9, about 10.3
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention provides a type I crystal of (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide having excellent TRPV1 antagonistic activity, a drug and a pharmaceutical composition containing this crystal, and a method for producing the crystal. The present invention provides a type I crystal of (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide that is excellent in at least one feature selected from the group consisting of storage stability, photostability and thermodynamic stability, that can be preferably obtained with industrially high reproducibility, yield and purity, and that is useful as a crystal of an active pharmaceutical ingredient.